Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Smith, Mitchell R ^a   Joshi, Indira ^a   Jin, Fang ^a   Obasaju, Coleman ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; GEMCITABINE; MONOCLONAL ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CD20 ANTIGEN; COLORING AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL ISOLATION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CLEARANCE; CLINICAL STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOMA CELL LINE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PLEURA FLUID; SCID MOUSE; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CELL PROLIFERATION; GENE TRANSLOCATION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORING AGENTS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; INHIBITORY CONCENTRATION 50; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POLY(ADP-RIBOSE) POLYMERASES; TETRAZOLIUM SALTS; THIAZOLES; TRANSLOCATION, GENETIC;

EID: 26844455684     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-103     Document Type: Article

References (27)

1. Smith MR: Non-Hodgkin's Lymphoma. Curr Probl Cancer 1996, 20:6-77.
2. Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon AC, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D: Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. British Journal of Haematology 2003, 120:970-977.
3. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R: Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004, 101:1835-1842.
4. Dumontet C, Morschhauser F, Solal-Celingy P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B: Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology 2001, 113:772-778.
5. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P: Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004, 5:45-49.
6. Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonodonna G, Seeber S, Nowrousian MR: Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 1999, 17:3786-3792.
7. Nabhan C, Krett N, Gandhi V, Rosen S: Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001, 13:514-521.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998, 16:2825-2833.
9. Alas S, Ng CP, Bonavida B: Rituximab Modifies the Cisplatin-mitochondrial Signaling Pathway, Resulting in Apoptosis in Cisplatin-resistant Non-Hodgkin's Lymphoma. Clinical Cancer Research 2002, 8:836-845.
10. Emmanouilides C, Jazirehi AR, Bonavida B: Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002, 17:621-630.
11. Smith MR, Fang J, Joshi I: Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Molecular Cancer Therapeutics 2004, 3:1693-1699.
12. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (IDEC_C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186.
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallay R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N England J Med 2002, 346:235-242.
14. Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
15. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
16. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24:2121-2143.
17. Smith MR, Xie T, Zhao-Zong Z, Joshi I: Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Clinical Cancer Research 2001, 7:400-406.
18. Kluin-Neilemans HC, Limpens J, Meerabux J, Beverstock GC, Jansen JH, de Jong D, Kluin PM: A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18) (q32;q21). Leukemia 1991, 85:221-224.
19. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A: A unique EBV-negative low-grade lymphoma line (WSUFSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet 1993, 70:62-67.
20. Freid J, Perez AG, Clarkson BD: Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. Journal of Histochemical Cytochemistry 1978, 26:921-933.
21. Brugge JS, Erikson RL: Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature 1977, 269:346-348.
22. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
23. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: Anti-CD20 antibody (IDEC-C2B8, ribuximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002, 87:33-43.
24. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W: S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Research 2001, 61:1065-1072.
25. Bartek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004, 5:792-804.
26. Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Research 2002, 62:2353-2358.
27. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS: Neutrophils contribute to the biologican antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research 2003, 9:5866-5873.